Immunitybio Net Working Capital from 2010 to 2024

IBRX Stock  USD 5.04  0.06  1.18%   
Immunitybio Net Working Capital yearly trend continues to be fairly stable with very little volatility. Net Working Capital is likely to outpace its year average in 2024. During the period from 2010 to 2024, Immunitybio Net Working Capital regression line of annual values had r-squared of  0.0009 and arithmetic mean of  37,855,270. View All Fundamentals
 
Net Working Capital  
First Reported
2010-12-31
Previous Quarter
235.8 M
Current Value
247.6 M
Quarterly Volatility
132.9 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Immunitybio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunitybio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 11.8 M, Interest Expense of 135.7 M or Selling General Administrative of 91.7 M, as well as many indicators such as Price To Sales Ratio of 6.7 K, Dividend Yield of 0.0 or Days Sales Outstanding of 1.8 K. Immunitybio financial statements analysis is a perfect complement when working with Immunitybio Valuation or Volatility modules.
  
Check out the analysis of Immunitybio Correlation against competitors.
For more information on how to buy Immunitybio Stock please use our How to Invest in Immunitybio guide.

Latest Immunitybio's Net Working Capital Growth Pattern

Below is the plot of the Net Working Capital of Immunitybio over the last few years. It is Immunitybio's Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunitybio's overall financial position and show how it may be relating to other accounts over time.
Net Working Capital10 Years Trend
Very volatile
   Net Working Capital   
       Timeline  

Immunitybio Net Working Capital Regression Statistics

Arithmetic Mean37,855,270
Geometric Mean62,083,602
Coefficient Of Variation351.10
Mean Deviation62,752,339
Median43,579,000
Standard Deviation132,908,020
Sample Variance17664.5T
Range607.9M
R-Value0.03
Mean Square Error19006.3T
R-Squared0.0009
Significance0.92
Slope889,976
Total Sum of Squares247303.6T

Immunitybio Net Working Capital History

2024247.6 M
2023235.8 M
2022-360.3 M
2021-34.6 M

About Immunitybio Financial Statements

Immunitybio investors use historical fundamental indicators, such as Immunitybio's Net Working Capital, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immunitybio. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Working Capital235.8 M247.6 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Immunitybio Stock Analysis

When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.